Translational Development of Protein Nanomedicines

Nanotechnology offers versatile platforms for loading anti-cancer drugs and delivering them to cells in a target specific manner, by conjugating with targeting ligands. Among the nanocarriers, proteins are extremely robust systems which are non-toxic in nature. The hydrophobic pockets of proteins such as albumin can be utilized for encapsulating hydrophobic drugs. Moreover, the hydrophilic functional groups can be used for conjugating ligands for targeted delivery of therapeutic molecules in a cell-specific manner. Further proteins can also be utilized to create novel architectures such as core-shell nanoparticles for loading more than one therapeutic molecule.

ABSORF: Protein-SorafenibNanomedicine (oral ABSORF)

Albumin based platform nanotechnology for enhancing the oral bioavailability of small molecule drugs such as Sorafenib, for anti-cancer applications.

  • Product entering into Regulatory safety profiling studies and further into Clinical trials

Our platform technology providing 2-3X enhanced bioavailability and low-toxicity will be a game changer for oral small molecule therapeutics specifically for BCS class 2 and class 4 drugs. Besides Sorafenib, many other molecules can be enhanced for their efficacy without add-on toxicity. Being a 100% indigeneous technology with demonstrated cGMP scalability, this product will have significant impact for patients from developing world.

Process Flow

Microscopy Images

Transmission Electron  and Scanning Electron Microscopic images of oral ABSORF nanoparticles

PK Profile

Single dose PK profile for ABSORF vs clinical control in SD rats showing 2 fold enhanced bioavailability

Simple Platform Nanotechnology for enhancing the oral bioavailability of small molecule drug.

Half-dose of nano-drug gives higher efficiency than current clinical drug. This will help to reduce the cost of therapy especially for life-long medication.

Nano-drug has low-toxicity and better efficiency.

100% indigeneous technology with patent protection.

MRI Study

MRI images of orthotopic liver tumor animals treated with ABSORF and clinical control on day 1, day 8 and day 15 of treatment.